Rimonabant FDA

What is Generic Acomplia and How to Buy for the best Price!!

The European Commission gave permission for the sale of Rimonabant Acomplia prescription weight loss drugs to treat obesity and weight loss with a BMI ( body mass index) of 30 or above as well as for smoking cessation treatments.

“The approval of Rimonabant (Generic version ofAcomplia) in the European Union is important news for obese and overweight patients with additional cardiometabolic risk factors such as type 2 diabetes or dyslipidaemia who will now have access to an innovative treatment option,” said Sanofi CEO Jean-François Dehecq.
Sanofi said that after the launch of Acomplia (Rimonabant) in the United Kingdom, it will be launched during the second half of 2006 in Denmark, Ireland, Germany, Finland and Norway as well.

Diet pill Acomplia (Rimonabant) is a miraculous multifunctional pill that helps you short out obesity as well as smoking. Acomplia diet pills work on the Endocannabinoid system, which controls appetite and energy expenditure (as well as the urge to smoke). This wonder pill selectively blocks some receptors in the Endocannabinoid system, thus creating a better balance which in turn suppresses appetite and the longing to overeat.

Free prescription for generic Acomplia
Our doctor prescribes online for free, and there is no doctor’s consultation fee.

Save on Shipping
Buy as many items as you like within 24 hours period of time, and pay only one low shipping price.

4RX.com- 1st provider for generic Acomplia

4rx pharmacy is the most reliable provider for Generic Acomplia.Buy with us and enjoy our best prices

While Sanofi’s diet drug Rimonabant (Acomplia / Zimulti) remains stalled at the FDA, a potential competitor currently in phase III trials, Merck’s MK-0364, now has an official generic name: Taranabant.

Taranabant is Merck’s cannabinoid-1 (CB-1) receptor inverse agonist, and from reports we periodically receive from participants in the phase III trial of this diet drug, taranabant is as effective for weight loss as rimonabant with fewer side effects.

An experimental weight loss medication in the same class as the drug Acomplia helped patients lose weight in a 12-week, phase II study, but side effects were common at higher doses.

Like Acomplia (rimonabant), which is approved for sale in Europe but not in the U.S., the Merck & Co. drug taranabant targets receptors in the brain linked to appetite.

Taranabant Trial

The double-blind study included 533 obese people randomly assigned to treatment with either placebo or 0.5 milligrams, 2 milligrams, 4 milligrams, or 6 milligrams of taranabant. All the participants received counseling on diet and exercise throughout the trial.

At the end of 12 weeks, the placebo-treated participants had lost the least weight and those treated with the highest dose of taranabant had lost the most.

Patients treated with 0.5 milligrams of the drug lost an average of 3.5 pounds, compared with 5 pounds among people treated with 2 milligrams of the drug and almost 9 pounds among those treated with 6 milligrams.

A total of 27% of patients who took 0.5 milligrams of taranabant lost 5% or more of their body weight, compared with 61% in the 6-milligram group.

But patients taking the higher dosages of the drug also had higher rates of side effects, including anxiety, nausea, and vomiting.

The new diet pill, if approved, won’t be for everyone. “This is not going to be a class of drugs that people take because they want to look good on vacation” and lose 10 pounds or so.

Rimonabant message board

Read what other customer say obout the new diet drug on our blog/message board 

The most effective way to reduce blood pressure and the risk for secondary diseases is to reduce weight. But most patients do not succeed in losing weight and keeping it off. A possible alternative could be an entirely new substance group which simultaneously blocks feelings of hunger and reduces blood lipid levels, thereby reducing the risk for cardiovascular diseases and type 2 diabetes.

 The new drug, called Rimonabant, has been tested in clinical trials for over two years in Europe and the USA. The European Director of the clinical trials, Professor Luc Van Gaal of the University Hospital in Antwerp, Belgium, presented results of this study at the 4th International Symposium on Obesity and Hypertension at the Max Delbr?nter for Molecular Medicine (MDC) Berlin-Buch.

Experiments with obese lab rats have shown that, the more they eat, the more endocannabinoids bind to the CB1-receptor, which is hyperactive in these animals. The result: The binding of endocannabinoids to CB1 increases appetite, Professor George Kunos demonstrated. He is from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), which is part of the National Institutes of Health (NIH) in Bethesda, Maryland, USA. Furthermore, Professor Kunos, who was unable to attend the Berlin meeting, showed in experiments with mice that blocking this receptor with the substance rimonabant reduces appetite. The animals become thin and stay that way despite being offered an overabundance of food. And rimonabant not only reduces the animals’ weight but also their blood pressure.

One-stop shopping fans should pay attention: a new drug that claims to help patiens stop smoking and lose weight at the same time. This drug it’s on the market since last year in Europe. The ultimate drug is called Rimonabant Acomplia, and its  produced by the French firm Sanofi-Synthelabo.
Just one pill has been discovered to stop both food and cigarette cravings enough to help people quit smoking and lose weight, and it also helps curb other unhealthy urges.
Named Rimonabant Acomplia the medicine in one study helped patiens who were overweight drop an average of 20 pounds and in another doubled the chances that smokers would quit.

Rimonabant (which is beeing sold on the market as Acomplia-in Europe) works by blocking the CB1 receptor, one of two receptors found in a newly described physiological system called the Endocannabinoid System (EC System), which  play an important role in the regulation of food intake and energy expenditure.

Scientist wondered whether a drug that halted this action might curb appetite, and in 2001, the first animal study was conducted at the National Institute of Alcohol Abuse and Alcoholism in Bethesda, Md.
When the normal mice were given rimonabant, which blocked their CB1 receptors, the mice reduced their food intake.In 2002, Sanofi-Synthelabo began testing on human patiens.

Rimonabant works by selectively targeting and blocking the CB1 receptors, helping normalize the over-activation of the EC system and making hunger or cigarette cravings more manageable.
This blocking of signals that control appetite is resulting in weight loss, improvement of cardiovascular/ metabolic risk factors in overweight/obese people and seems to reduce tobacco addiction without post cessation weight gain in patiens who smoke.

Based on the available data from lots of clinical trials, Rimonabant (Acomplia, Zimulti) is an extremely safe drug with minor side effects such as nausea, mood swings, anxiety and dizziness.
Rimonabant is recommended to be taken along with regular exercise and a diet regime for optimum results. People with a Body Mass Index (BMI) greater than or equal to 30kg/m2 can benefit from taking a daily pill of Rimonabant of 20mg along with proper exercise and diet.Various trials conducted have shown remarkable results making Rimonabant (Acomplia, Zimulti) one of the most sought after anti-obesity medications worldwide.

We all know pill popping isn’t the answer when it comes to losing weight and keeping if off. But clinical trials with a new anti-obesity drug look promising. The drug, called rimonabant, was developed after scientists noticed that cannabis smokers often had increased appetites and frequently experienced the ‘munchies’.

They worked on the idea that if substances from cannabis called cannabinoids stimulated appetite, blocking the cannabinoid receptors in the brain might reduce appetite.

Furthermore, blocking these receptors might also help people to give up smoking as these receptors not only appear to be involved in controlling food intake, but also have a role to play in tobacco dependence.

Earlier trials with the drug, which works by blocking cannabinoid receptors in the brain, have already shown promising results. But now a new study published in medical journal The Lancet, confirms the drug can help with weight loss and reduce the risk factors associated with heart disease.

In the study, more than 1,500 obese people were given a calorie-controlled diet, together with either 5mg or 20mg of rimonabant each day or a dummy drug. After one year, two thirds of the participants taking the largest dose had lost at least 5 percent of their weight. Better still, of these, 39 percent lost more than 10 percent. Meanwhile, patients on the 20mg dose lost on average, 4cm from their waist and risk factors for heart disease including raised cholesterol, insulin resistance and the presence of metabolic syndrome improved.

Professor Luc Van Gaal who led the study says, “In this study, treatment with rimonabant over one year led to sustained, clinically meaningful weight loss, reduction in waist circumference and associated improvements in several cardiovascular risk factors.”

Weight Loss Resources says…

It’s great that research continues to be carried out in an effort to help find a drug that can aid weight loss. However, it’s unlikely we’ll ever be in a situation where diet and exercise become redundant in the fight against obesity. Finding a miracle pill that enables us to lose weight while constantly overindulging on a poor diet and doing no exercise is still a long way off. Even in this study, the participants had to follow a calorie-controlled diet!

Related articles: New diet pill acomplia

Acomplia online

For the next three or four years Sanofi-Aventis sais that they will not try  to sell diet medication acomplia rimonabant in the United States. The company declared that on Sept. 17th. But they also showed that they still have  high expectations for acomplia rimonabant, specially as a treatment for type 2 diabetes.

Sanofi’s head of research Marc Cluzel said:”I believe  in Acomplia rimonabant because it is a unique product,” this happened in front of all the reporters and analysts at a presentation on the company’s research and development program.

Meanwhile Acomplia Rimonabant was launched  Europe’s market in 2006 and it is now  available also in of other states,the producer of the drug, Sanofi, retired its application,that had the purpose to acced with acomplia in the United States ,after  FDA  unanimously recommended the rejection of  the drug because of the side-effects including depression and suicidality.

Sanof declared that they planned to use approximately 11,000 of the 17,000 people for this trial, and they have clues that the result  this study will be available to share with the FDA in 2010.

Cluzel declared that  Sanofi expects to refile its application with the FDA after longer-term data on the use of Acomplia rimonabant has been gathered from the large CRESCENDO trial, which got underway in December 2005.

But despite the fact Sanofi got some bad news related with the near-term future of Acomplia rimonabant as a diet drug, the company said that their new plans are now to aggressively  press ahead with some new studies in order to aimed gain the  approval for using acomplia rimonabant as a main-line treatment of type 2 diabetes.

Sanofi is also  planning to launch a trial to compare Acomplia rimonabant to Merck’s diabeties medication named Januvia in the first quarter of 2008 .

The company said they are hopping to file for approvals around the world for Acomplia rimonabant as a treatment for diabetes in 2009.

Sanofi also declared that it also hopes to file for regulatory approval of a medication that is a combination of Acomplia rimonabant and a cholesterol-lowering statin in 2011. 

The new and exciting about Acomplia is that it functions very differently to the other medication in the same field such as  Reductil and Xenical.  Reductil is also an appetite srepressant but it does not work in the same way as Acomplia does. Acomplia it really works on  the  receptors that are located in the brain and which control the appetite. Acomplia it is produced by the firm Sanofi-Aventis,which is located in France.

A few years back another very big drug company named Merck decided to produs a drug similar that would stimulate the brain receptors and in this way to control the desire to eat in the same way as acomplia and have been extreamly busy with a phase 3 clinical trial. This new diet medication is named taranabant and the wisspers that we have heard from Ukmedix News sais that the results have been very good.

Almost two and a half thousand men and women have been testing the medication in the last 2 years and based on the power of the clinical results all the world  expectes that Merck will file a good application in order to be  approved the new drug(rival of acomplia) to the Food & Drug Administration next year, possible in the second quarter of 2008. As is being practiced for everyone very little informations have been given to the media by the drug company Merck that refers to the results of the trials.However from this  little information coming from the people that participated in the clinical trials it seems that things are doing very well.

Drugs,like acomplia, that help you to loss weight are in great demand all over the globe as so many developed states are dealling with a great  number of obese people. Obesity generates costs in the whole world at the level of billions of pounds each year in medical bills and the financial returns on weight loss medication have great potential.

Importantt scientific advances have been done in drugs(such as acomplia) over the last few years that specifically work on the receptors located in the brain and  companies that produce drugs are  investing very much in such a type of research. It is expected that over the next few decades the world will see lots of drugs on the market to cure a whole list of ailments from a neurological angle as opposed to a physical point of view.

Buy Rimonabant Acomplia for effective weight loss

Rimonabant Acomplia diet pill is the first in a class of a drug called cannabinoid receptor type1 (CB1) Blockers. Rimonabant (acomplia) diet pill helps people to winning the weight loss battle.

Abdominal fat is a Kingpin of heart disease. Acomplia Rimonabant diet pill reduces fat located in the abdominal area. A substantial drop in weight attributed to taking Acomplia Rimonabant diet pill, constituted lower triglycerides, and improved the HDL cholesterol levels, as well as Rimonabant helped desensitize 

Recent two year study involving Rimonabant (Acomplia) diet pill, The Rimonabant Side effects for those who taking Rimonabant Acomplia, were mild. Some of the side effects of Rimonabant (acomplia) included irritability, depression, and nausea. Acomplia is such a new drug which has few side effects with compare to advantages. As with all drugs, come risks. With obesity come risks.  Do the risks from obesity outweigh the risks involved with Rimonabant (acomplia) diet pill? These are questions that the dieter should discuss with their doctors.

Purchase Rimonabant diet pill and start weight loss from today. click here to Order Rimonabant

16 October 2007 11:45

Dr Ian Paisley who is the First Minister , newly visited  the main quarters of Almac,one of the producers of rimonabant, in Craigavon, County Armagh. It was the first visit to the company for Dr Paisley.The company  employs 2,000 people across Northern Ireland, Scotland and the United States.

The company has five divisions which are working with over 600 companies from all over  the world, which includes all the international leaders in the sectors pharmaceutical and biotech . Almac ensure a large range of services which includes pharmaceutical research and development ,drug discovery, diagnostics,  clinical trials and manufacture producted drugs,such as rimonabant.

Dr Paisley first words were : “It is exciting to watch such home grown expertise being used to draw and produce medical and healthcare treatments which are cutting edge and being used all over the world. Is good to comment this important world class standard of research and development which is taking place here in Northern Ireland, and it is  indicates that above many dikes, our system of education and work ethic is showing that entrepreneurship and innovation spirit is living very well. We, the executive and assembly will have to work very hard to build an milieu where we can develop and boom age more success stories like Almac,one of the producers of rimonabant.”

Almac Group Chairman Sir Allen McClay met with Dr Paisley and so they’ve done as well the executives from all the units bussines off the company’s. Among them Professors Tim Harrison, Paul Harkin and Dr Richard Kennedy, all of  them are leaders in our programmes of research and development which  includes our global renowned work on cancer diagnostics. They exposed Dr Paisley a full storyon the division’s work,specialy about the workwith rimonabant.

Sir Allen McClay the Chairman of the Almac Group,olso knowed as a producer of rimonabant, said a few words: “We are honoured to have here today at Almac Headquarters the First Minister. The centre of all our work is the innovation and  we will continue to advance here in Craigavon, the development of future medicines,such as rimonabant. Our company now has a distinct international pozition; 29 nationalities are part off the Almac family, but  we still have and allways will our Northern Ireland identity.”

Paying personal tribute to founder of Almac, Sir Allen McClay, ,Dr Paisley said: “He is an example to all the world  of how every person in Northern Ireland can succed.”

How can I buy Rimonabant/Acomplia/Zimulti ?

Acomplia Rimonabant is approved in Europe and UK and can be legally purchased through prescription. This drug Rimonabant Acomplia is available for sale in all 25 European countries including UK. Also it can be shipped to US via the online pharmacies.

Buying Rimonabant Acomplia helps you to treat obesity but this new class weight loss drug Rimonabant Acomplia is not yet approved for smoking cessation. It is still waiting for the approval from European union for smoking cessation.

Advantages of Rimonabant

Acomplia Rimonabant has dual effect on Obesity and Weight Management. It works equally for weight loss and maintain your weight as well. Online Rimonabant Acomplia does not only facilitate the ability to control your weight but fosters the ability to fend off weight gain. Lot of tests and trials conducted has indicated that people taking Rimonabant have significant weight loss results with very mild rimonabant side effects. Tests indicate that amongst those who took Rimonabant Acomplia for twenty-four months, one third lost five to ten percent of their body weight.

Rimonabant Acomplia drug in a clinical test, helps you lose weight and it also helps protect your heart in many ways. Trials have shown that 33% of people on Rimonabant Acomplia lost 10% of body weight and kept their weight down for two years - this is a record, no other diet drug has managed to keep a person’s weight down for so long. A weight loss of 5 to 10 percent can significantly improve risk factors for obesity-related diseases and delay or prevent type 2 diabetes in persons at high risk.

Buy Rimonabant Acomplia today and start losing weight!

Side Effects of Rimonabant

Rimonabant Acomplia is a new anti-obesity pill with helping people to lose weight. Like with other drugs rimonabant acomplia has also very mild side effects such as depression, anxiety and irritability coupled with dizziness. Side effects of Rimonabant Acomplia are mostly minor and temporary this is not to be worried about as the plus factor is too large.
An experimental drug, Acomplia or Rimonabant is primarily a diet pill but it works differently by affecting the brain’s reward system. Other than weight loss Rimonabant in UK also reduces triglyceride levels and increases good cholesterol levels thus protecting from cardio-vascular diseases.
Rimonabant Acomplia was found to increase blood pressure even as it facilitated weight loss. Some 40 per cent of Sanofi’s Rimonabant test subjects dropped out during the first year of the obesity trials. “Some complained of nausea, diarrhea, vomiting, dizziness and headaches, as well as mood disorders including anxiety and depression” according to the New Scientist.
Order Rimonabant UK online from us for healthy and safe weight loss!

Rimonabant Acomplia aimed at helping patients lose weight and quit smoking.
Rimonabant Acomplia is the first of a new class of drugs targeting the endocannabiniod system, which helps to regulate pleasure, relaxation, and pain tolerance.
Side effects of Acomplia were described as minor and temporary, the most frequent being diarrhea, nausea, vomiting and dizziness. More severe anticipated side effects, especially depression, did not materialize. it caused nausea in 13% of patients, vs. in 4% of those who got placebo.
Anxiety and diarrhea also occurred at a higher rate in patients taking rimonabant than in placebo casdepression and anxiety scores as measured by the Hospital Anxiety and Depression (HAD) scale.
Rimonabant Acomplia was found to increase blood pressure even as it facilitated weight loss. Some 40 per cent of Sanofi’s test subjects dropped out during the first year of the obesity trials. “Some complained of nausea, diarrhea, vomiting, dizziness and headaches, as well as mood disorders including anxiety and depression,” according to the New Scientist.